Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwMyeloma 2015 | Minimal residue disease (MRD) in multiple myeloma

Rafael Fonseca • 11 Apr 2015
iwMyeloma 2015
Multiple Myeloma

At the Myeloma 2015 meeting, Dr Rafael Fonseca (Mayo Clinic, Scottsdale, AZ) considers how detecting and monitoring minimal residue disease (MRD) in multiple myeloma may inform and tailor therapeutic decisions. Clinically important methods to determine MRD include flow cytometry and next-generation sequencing.

More from Rafael Fonseca

The eMMpower Consortium: real-world data to understand the characteristics and patterns of myeloma 1:01
The eMMpower Consortium: real-world data to understand the characteristics and patterns of myeloma
Rafael Fonseca • 20 Sep 2025
Cilta-cel versus conventional treatment regimens in multiple myeloma: a real-world study 1:11
Cilta-cel versus conventional treatment regimens in multiple myeloma: a real-world study
Rafael Fonseca • 20 Sep 2025
Circulating tumor DNA assessment in multiple myeloma: emerging evidence for clinical utility 1:50
Circulating tumor DNA assessment in multiple myeloma: emerging evidence for clinical utility
Rafael Fonseca • 20 Sep 2025
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more 14:14
Clinical trial updates in myeloma: anti-CD38 mAbs, ADCs, treating smoldering myeloma & more
Adriana Rossi et al. • 12 Apr 2025

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals